Annals of Thoracic Medicine
GUIDELINES
Year
: 2008  |  Volume : 3  |  Issue : 6  |  Page : 100--103

Treatment for small-cell lung cancer


Ahmed Saadeen1, Abdul-Rahman Jazieh2 
1 Riyadh Military Hospital, Riyadh, Saudi Arabia
2 King Abdulaziz Medical City, Riyadh, Saudi Arabia

Correspondence Address:
Ahmed Saadeen
Department of Oncology (Bldg 1), Riyadh Military Hospital, P.O. Box 7897, Riyadh 11159
Saudi Arabia

Small-cell lung cancer (SCLC) accounts for 13-20% of all lung cancers. Stongly associated with smoking and initially responsive to treatment, it results in death within 2-4 months without treatment. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. Extensive-stage disease is primarily treated with chemotherapy and has a high initial response rate of 60-70% but the median survival is only 10 months. All patients achieving a complete remission should be offered prophylactic cranial irradiation. Relapsed or refractory SCLC has a uniformly poor prognosis.


How to cite this article:
Saadeen A, Jazieh AR. Treatment for small-cell lung cancer.Ann Thorac Med 2008;3:100-103


How to cite this URL:
Saadeen A, Jazieh AR. Treatment for small-cell lung cancer. Ann Thorac Med [serial online] 2008 [cited 2020 Sep 21 ];3:100-103
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2008;volume=3;issue=6;spage=100;epage=103;aulast=Saadeen;type=0